Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 1/2 6Phase 3 3Phase 1 2Phase EARLY_PHASE1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Breast 2Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Lung Neoplasms 1Localized Muscle Invasive Bladder Urothelial Carcinoma 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × sacituzumab govitecan × Genitourinary × Clear all
NCT04794699 2026-04-09

Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion

IDEAYA Biosciences

Phase 1 Active not recruiting
169 enrolled
GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT05833867 2026-03-13

Adaptive RADiation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer

Case Comprehensive Cancer Center

Phase 1 Recruiting
20 enrolled
Genitourinary

Localized Muscle Invasive Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡